Methyl 5-methyl-4-oxohex-2-enoate | 152754-30-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Methyl 5-methyl-4-oxohex-2-enoate
• 英文别名: 2-Hexenoic acid, 5-methyl-4-oxo-, methyl ester, (E)-；methyl (E)-5-methyl-4-oxohex-2-enoate
• CAS: 152754-30-8
• 化学式: C₈H₁₂O₃
• 分子量: 156.181
• InChiKey: MXGDZSJYAGQXTM-SNAWJCMRSA-N

物化性质

• 沸点：
  231.3±23.0 °C(Predicted)
• 密度：
  1.006±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-pyrroline N-oxide 、 Methyl 5-methyl-4-oxohex-2-enoate 以 二氯甲烷 为溶剂， 反应 72.0h， 以60%的产率得到(2R,3R,3aR)-2-Isobutyryl-hexahydro-pyrrolo[1,2-b]isoxazole-3-carboxylic acid methyl ester
  参考文献：
  名称：

  硝酮环加成对γ-氧代α，β-不饱和酯的区域选择性

  摘要：

  据报道，环状硝酮1和2的1，3-偶极环加成有几种γ-氧代α，β-不饱和酯5-10。观察到区域异构体的强烈优势是偶极子的氧原子附着在β-酯位置上。这种高区域选择性归因于空间因素。某些主要环加合物的羰基还原是制备某些羟基衍生物的好方法，这些羟基衍生物在相同硝酮与相应的γ-羟基α，β的环加成中并未形成或仅以较小的立体异构体形式获得。 -不饱和酯。

  DOI：

  10.1016/s0040-4020(98)00628-0
• 作为产物：
  描述：

  5-Methyl-4-oxo-3-tosylhexanoic acid 在 盐酸 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 生成 Methyl 5-methyl-4-oxohex-2-enoate
  参考文献：
  名称：

  Lithium 3-Lithio-3-tosylalkanoates: .beta.-Acylvinyl Anion Equivalents of .beta.-Lithiated .alpha.,.beta.-Unsaturated Carboxylic Acids

  摘要：

  The dilithiation of beta-tosylated propanoic, 2-methylpropanoic, and butanoic acid 10 with n-butyllithium at -78 degrees C leads to the corresponding lithium 3-lithio-3-tosylalkanoates 11. They react with different electrophilic reagents (deuterium oxide, iodine, trimethylchlorosilane, alkyl halides, and acyl chlorides) to give the corresponding 3-substituted tosylated alkanoic acids 12. When carbonyl compounds are allowed to react with intermediates 11 followed by in situ lactonization with trifluoracetic anhydride and base-promoted elimination alpha,beta-butenolides are obtained. This methodology is applied to the direct synthesis of the rosefuran lactone precursor 14cg, the O-benzyl derivative of (+/-)-umbelactone (14ch), and (+/-)-andirolactone (14ci). The alkylation and acylation reactions of organolithium compounds 11 followed by esterification with hydrogen chloride in methanol and treatment with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) afford alpha,beta- and/or beta,gamma-unsaturated esters 17 and/or 18 and unsaturated 4-keto esters 19, respectively. The last methodology has been applied to the synthesis of the unsaturated 4-keto ester 19ae precursor of the seco acid of (+/-)-pyrenophorin (22).

  DOI：

  10.1021/jo00090a043

文献信息

• Cobalt(II) catalysed reaction of alkenes with aliphatic aldehydes and molecular oxygen: scope and mechanism
  作者：Sonika Bhatia、T. Punniyamurthy、Beena Bhatia、Javed Iqbal

  DOI：10.1016/s0040-4020(01)87194-5

  日期：1993.7

  prepared using Schiff's bases derived from aromatic aldehydes and amines or α-aminoesters. These complexes are versatile catalyst for the reaction between aliphatic aldehydes and various alkenes. The outcome of the reaction is controlled by the electronic nature of the alkene as the electron deficient alkenes undergo oxidative addition of aldehydes followed by dioxygen incorporation to yield 2-hydr

  可以使用衍生自芳族醛和胺或α-氨基酯的席夫碱制备各种钴（II）配合物。这些络合物是脂肪族醛与各种烯烃之间反应的通用催化剂。反应的结果受烯烃的电子性质控制，因为缺电子的烯烃经历醛的氧化加成反应，然后引入双氧生成2-羟基（酰氧基）-4-氧酸酯或腈，而未活化或富电子的烯烃则提供了相应的环氧化物。这些反应是通过自由基途径进行的，并提出了一种常见的酰基钴中间体，用于形成4和环氧化物7。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
  申请人：Cellix Bio Private Limited

  公开号：US20160152553A1

  公开（公告）日：2016-06-02

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of multiple sclerosis and psoriasis.

  该发明涉及公式I和公式II的化合物或其药用可接受的盐，以及其多晶形、溶剂合物、对映体、立体异构体和水合物。包括公式I或公式II化合物的有效量的药物组合物；以及用于治疗或预防多发性硬化的方法可以制成口服、颊部、直肠、局部、经皮、经粘膜、静脉、肠道、糖浆或注射剂的制剂。这些组合物可用于治疗多发性硬化和银屑病。
• 4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT
  申请人：Confluence Life Sciences Inc.

  公开号：US20150203499A1

  公开（公告）日：2015-07-23

  The present disclosure provides 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds, pharmaceutically acceptable salts, solvates and pharmaceutical compositions of compounds embraced by Formula (I), providing a therapeutic benefit to subjects with disease conditions, especially cancer, wherein R 1 and R 2 are as defined in the detailed description.

  本公开提供4-烷氧基/芳氧基-5-取代-吡咯蒽嘧啶化合物、药学上可接受的盐、溶剂和由式(I)所包含的化合物组成的制药组合物，为患有疾病情况的受试者提供治疗益处，特别是癌症，其中R1和R2如详细说明中所定义。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND GOUT
  申请人：Alapati Mohan Murali

  公开号：US20160332950A1

  公开（公告）日：2016-11-17

  The disclosures herein provide compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI and Formula VII or its pharmaceutical acceptable compositions and salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. The pharmaceutical compositions may be formulated for oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, nanoparticle, buccal administration or transdermal administration. Such compositions may be used to treatment of urea cycle disorders and gout or its associated complications.
• US9102649B1
  申请人：——

  公开号：US9102649B1

  公开（公告）日：2015-08-11